Regeneron Pharmaceuticals (NASDAQ:REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody ...
Jianhui Li of Wanhuida Intellectual Property reports on a ruling by the China National Intellectual Property Administration that could shed light on the patent examination standards concerning cutting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results